{
    "text": "[\"title : evaluation of the safety and immunogenicity of glaxosmithkline biologicals ' hpv vaccine qqq when administered in healthy females aged qqq â€“ qqq years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing . cervarix qqq ( hpv ) : glaxosmithkline ( gsk ) biologicals ' vaccine against human papillomavirus qqq and qqq qqq : non-approved schedule qqq : standard approved qqq , qqq , qqq schedule rationale : the aim of this study was to evaluate the safety and immunogenicity of different formulations of hpv vaccine and of different administration schedules in healthy young females aged qqq to qqq years , as to the standard approved qqq hpv vaccination regimen.this ctrs presents the results of immunogenicity and safety analyses for the active phase of the study ( up to month qqq ) and the extended safety and immunogenicity follow-up phase up to month qqq ; it will be updated when data from the last time point become available.. phase : i/ii study period :\"]",
    "sequences": [[67, 430, 5, 2, 187, 6, 2866, 5, 14735, 215, 24417, 369, 1, 171, 263, 7, 597, 1513, 322, 1, 1, 83, 123, 41, 608, 1326, 6, 41, 608, 1032, 34, 45, 10, 2, 233, 1326, 6, 1032, 4, 1, 9, 24417, 8, 67, 14735, 9, 8, 215, 369, 569, 584, 1, 6, 1, 1, 67, 1326, 1, 67, 233, 3928, 1, 3, 1, 3, 1, 1326, 6554, 67, 2, 428, 5, 37, 25, 14, 10, 229, 2, 187, 6, 2866, 5, 241, 3195, 5, 24417, 369, 6, 5, 241, 257, 3269, 7, 597, 1124, 1513, 322, 1, 10, 1, 83, 3, 34, 10, 2, 233, 3928, 1, 24417, 897, 26994, 4305, 2, 96, 5, 2866, 6, 187, 553, 17, 2, 253, 327, 5, 2, 25, 9, 275, 10, 373, 1, 8, 6, 2, 1737, 187, 6, 2866, 112, 327, 275, 10, 373, 1, 27, 164, 1101, 54, 10332, 171, 188, 44, 2, 886, 86, 461, 2382, 327, 67, 12227, 25, 104, 67]]
}
